Piper Jaffray Companies restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report report published on Monday morning, Stock Target Advisor reports. They currently have a $104.00 price target on the stock.
Several other equities analysts have also commented on the company. Wells Fargo & Co reissued a buy rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Oppenheimer boosted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a research report on Monday, November 25th. William Blair upgraded shares of Crispr Therapeutics from a market perform rating to an outperform rating in a research report on Tuesday, November 19th. Zacks Investment Research cut shares of Crispr Therapeutics from a hold rating to a sell rating in a research note on Monday, September 30th. Finally, BidaskClub lowered shares of Crispr Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, December 13th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $69.54.
Shares of Crispr Therapeutics stock opened at $65.39 on Monday. The business’s fifty day simple moving average is $61.44 and its 200-day simple moving average is $49.16. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market cap of $3.64 billion, a PE ratio of -19.01 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, equities analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other news, President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 over the last three months. 21.40% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Crispr Therapeutics during the 2nd quarter worth $41,000. Aperio Group LLC acquired a new position in Crispr Therapeutics during the 2nd quarter worth approximately $153,000. Swiss National Bank boosted its holdings in Crispr Therapeutics by 28.6% in the 2nd quarter. Swiss National Bank now owns 48,600 shares of the company’s stock worth $2,289,000 after acquiring an additional 10,800 shares during the period. National Asset Management Inc. purchased a new position in Crispr Therapeutics in the 2nd quarter worth approximately $362,000. Finally, Wells Fargo & Company MN grew its position in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after acquiring an additional 116,540 shares in the last quarter. Institutional investors and hedge funds own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What is a resistance level?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.